Nikkei 225 Intelligence
2026-06-30 CHUGAI PHARMACEUTICAL CO.,LTD. “We have begun collaborative research using real-world data an … 続きを読む
2026-06-19 CHUGAI PHARMACEUTICAL CO.,LTD. “Sparsentan has submitted an application for manufacturing and … 続きを読む
2026-06-19 CHUGAI PHARMACEUTICAL CO.,LTD. “Regarding the approval of the anti-CD20 monoclonal antibody & … 続きを読む
2026-06-19 CHUGAI PHARMACEUTICAL CO.,LTD. “Avastin has received approval for an additional indication, b … 続きを読む
2026-06-12 CHUGAI PHARMACEUTICAL CO.,LTD. “Tecentriq has applied for an expanded indication as maintenan … 続きを読む
2026-05-26 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical receives the "Imperial Invention A … 続きを読む
2026-05-25 CHUGAI PHARMACEUTICAL CO.,LTD. “Organizational changes and personnel announcements.”
2026-05-18 CHUGAI PHARMACEUTICAL CO.,LTD. “Alecensa has received approval for the world's first cros … 続きを読む
2026-05-18 CHUGAI PHARMACEUTICAL CO.,LTD. “FoundationOne CDx cancer genome profiling has been approved a … 続きを読む
2026-05-18 CHUGAI PHARMACEUTICAL CO.,LTD. “Alecensa has received approval for the world's first cros … 続きを読む